Get the Stockscreener App
78.79
4.89%
3.67
After Hours:
78.05
-0.74
-0.94%
Haemonetics Corp stock is traded at $78.79, with a volume of 938.80K.
It is up +4.89% in the last 24 hours and up +53.92% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$75.12
Open:
$75.73
24h Volume:
938.80K
Relative Volume:
0.99
Market Cap:
$3.69B
Revenue:
$1.35B
Net Income/Loss:
$163.34M
P/E Ratio:
24.05
EPS:
3.2763
Net Cash Flow:
$189.17M
1W Performance:
+7.21%
1M Performance:
+53.92%
6M Performance:
+17.74%
1Y Performance:
-7.77%
1-Day Range:
$75.62
$79.41
1-Week Range:
$73.04
$79.41
52-Week Range:
$47.31
$89.69
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
78.79 | 3.52B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Teleflex, Solventum, Haemonetics, Centene, and Molina Healthcare Shares Skyrocket, What You Need To Know - Barchart.com
Haemonetics stock holds Buy rating at BTIG on plasma segment strength - Investing.com
HAE: BTIG Reiterates Buy Rating with $88 Price Target | HAE Stoc - GuruFocus
How currency fluctuations impact Haemonetics Corporation stockEarnings Risk Report & Daily Oversold Stock Bounce Ideas - newser.com
How Haemonetics Corporation (HAZ) stock reacts to fiscal policiesOptions Play & Long-Term Investment Growth Plans - newser.com
Can Haemonetics Corporation stock deliver consistent earnings growthAnalyst Upgrade & Accurate Intraday Trade Tips - newser.com
Why retail traders accumulate Haemonetics Corporation stockWeekly Volume Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Haemonetics Corporation stock at risk of policy regulation2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com
How Haemonetics Corporation stock correlates with oil marketsWeekly Stock Recap & Low Drawdown Momentum Ideas - newser.com
How Haemonetics Corporation stock benefits from digital adoptionMarket Risk Report & Smart Allocation Stock Tips - newser.com
Why Haemonetics Corporation stock could outperform next yearEarnings Risk Summary & Weekly Watchlist for Consistent Profits - newser.com
Key metrics from Haemonetics Corporation’s quarterly dataWeekly Risk Report & Reliable Volume Spike Alerts - newser.com
Is Haemonetics Corporation stock a buy on weakness2025 Top Decliners & Step-by-Step Swing Trade Plans - newser.com
How Haemonetics Corporation stock reacts to oil prices2025 Technical Patterns & Risk Managed Investment Signals - newser.com
How Haemonetics Corporation stock reacts to stronger dollar2025 Risk Factors & Growth Focused Investment Plans - newser.com
Can Haemonetics Corporation (HAZ) stock stage a strong rebound this quarter2025 Dividend Review & Weekly Top Performers Watchlists - newser.com
Haemonetics (HAE) Price Target Increased by 11.07% to 88.03 - MSN
Interpreting Haemonetics (HAE) International Revenue Trends - Yahoo Finance
Is Haemonetics Corporation (HAZ) stock among top earnings playsJuly 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
Using data filters to optimize entry into Haemonetics CorporationMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
A Look at Haemonetics’s (HAE) Valuation Following a 51% 30-Day Share Price Surge - Yahoo Finance
Using flow based indicators on Haemonetics CorporationWeekly Profit Analysis & Community Supported Trade Ideas - newser.com
Is Haemonetics’ (HAE) Shift to Profitability and Buybacks a New Capital Allocation Play? - simplywall.st
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
Can Haemonetics Corporation (HAZ) stock test all time highsLong Setup & Real-Time Chart Breakout Alerts - newser.com
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $75 - 富途牛牛
How Haemonetics Corporation stock compares to industry benchmarksMarket Trend Summary & AI Powered Market Entry Ideas - Fundação Cultural do Pará
Why Haemonetics Corporation (HAZ) stock could rally stronglyQuarterly Investment Review & Safe Investment Capital Preservation Plans - Fundação Cultural do Pará
Blood Processing Equipments Market Projections 2025-2032: Key - openPR.com
Haemonetics Corp : Raymond James Raises Targe - 富途牛牛
Raymond James raises Haemonetics stock price target to $90 on strong results - Investing.com
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $75 to $90 - 富途牛牛
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):